U.S. Markets closed
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • Dow 30

    34,777.76
    +229.23 (+0.66%)
     
  • Nasdaq

    13,752.24
    +119.39 (+0.88%)
     
  • Russell 2000

    2,271.63
    +30.21 (+1.35%)
     
  • Crude Oil

    64.82
    +0.11 (+0.17%)
     
  • Gold

    1,832.00
    +16.30 (+0.90%)
     
  • Silver

    27.57
    +0.10 (+0.38%)
     
  • EUR/USD

    1.2167
    +0.0098 (+0.8152%)
     
  • 10-Yr Bond

    1.5770
    +0.0160 (+1.02%)
     
  • Vix

    16.69
    -1.70 (-9.24%)
     
  • GBP/USD

    1.3990
    +0.0098 (+0.7037%)
     
  • USD/JPY

    108.5400
    -0.5450 (-0.4996%)
     
  • BTC-USD

    58,593.36
    +757.91 (+1.31%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

Oncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast Cancer

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oncolytics Biotech Inc (NASDAQ: ONCY), together with SOLTI, has announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study evaluating pelareorep plus checkpoint blockade therapy.

  • These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.

  • Data from 20 HR+/HER2- early-stage breast cancer patients included in AWARE-1's first two cohorts are presented.

  • These patients were treated with pelareorep and letrozole without (cohort 1) or with (cohort 2) Roche's PD-L1 inhibitor atezolizumab (Tecentriq) before surgery.

  • Pelareorep treatment in cohort 1 induced the generation and expansion of T cell clones, promoted tumor infiltration of CD8+ T cells, and increased the CelTIL score, a measure of tumor cellularity and inflammation associated with favorable clinical outcomes.

  • Data from cohort 2 patients demonstrated that pelareorep and atezolizumab generated an anti-cancer immune response in the tumor and peripheral blood.

  • Notably, cohort 2 met the pre-specified success criteria for the study's primary endpoint (50% of patients with over 30% increase in CelTIL score)—six of ten patients achieved at least a 30% increase in CelTIL score following treatment.

  • Pelareorep reversed immunosuppressive tumor microenvironments and promoted immune effector cell infiltration into solid tumors.

  • Tumor-cell-specific pelareorep replication was observed in all evaluated patients following intravenous pelareorep administration.

  • 70% of all cohort 1 and 2 patients (n=20) saw an increase in CelTIL from baseline to surgery.

  • Compared to cohort 1, cohort 2 patients had a higher ratio of CD8+ T cells to regulatory T cells, suggesting pelareorep and checkpoint inhibition enhance inflammation within the tumor microenvironment.

  • Oncolytics will host a Key Opinion Leader event today at 2:00 pm E.T.

  • Price Action: ONCY shares are down 8.9% at $3.65 on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.